OneSource Specialty Pharma shareholders approve auditor appointment, resolutions
- Shareholders approved B S R & Co LLP as statutory auditors for a 5-year term with 96.23% votes in favour
- Special resolution for additional MD remuneration passed with 94.46% support, facing 5.54% opposition
- Material related party transactions with Strides Pharma entities approved with 99.99% votes in favour
- Re-appointment of Neeraj Sharma as director secured 97.04% shareholder approval
*this image is generated using AI for illustrative purposes only.
OneSource Specialty Pharma Limited shareholders approved the appointment of M/s B S R & Co LLP as statutory auditors for a 5-year term at the 19th Annual General Meeting held on September 23, 2026. The resolution received 96.23% votes in favour from the total valid votes cast.
The virtual meeting, which commenced at 5:00 pm IST and concluded at 6:02 pm IST, saw the adoption of financial statements for the fiscal year ended March 31, 2026. Neeraj Sharma, Chief Executive Officer and Managing Director, briefed attendees on strategic updates and the company’s annual performance.
Statutory auditor appointment details
Shareholders approved the appointment of M/s B S R & Co LLP, Chartered Accountants, to hold office from the conclusion of the 19th AGM until the conclusion of the 24th AGM. This constitutes a 5-year tenure. The firm has a strength of over 4,000 personnel and 170 partners, serving several listed companies including those in the Pharma and Life Sciences sector.
Key resolutions transacted
The agenda included the re-appointment of Neeraj Sharma as a retiring director and approval for additional remuneration payable to the Managing Director. Additionally, shareholders voted on commission for non-executive independent directors and material related party transactions with Strides Pharma Science Ltd and Strides Pharma Inc, USA.
| Resolution Type | Item | Status | Votes In Favour (%) | Votes Against (%) |
|---|---|---|---|---|
| Ordinary | Adoption of Financial Statements | Passed | 99.75 | 0.25 |
| Ordinary | Re-appointment of Neeraj Sharma | Passed | 97.04 | 2.96 |
| Ordinary | Appointment of Statutory Auditors | Passed | 96.22 | 3.78 |
| Special | Additional Remuneration for MD | Passed | 94.46 | 5.54 |
| Special | Commission for Non-Executive Directors | Passed | 98.40 | 1.60 |
| Ordinary | Material RPTs with Strides Pharma Science Ltd | Passed | 99.99 | 0.01 |
| Ordinary | Material RPTs with Strides Pharma Inc, USA | Passed | 99.99 | 0.01 |
Governance and compliance details
The meeting was chaired by Arun Kumar, Chairperson of the Board. Trisha A, Company Secretary and Compliance Officer, confirmed compliance with the Companies Act, 2013, and SEBI regulations. The Auditor's Report for both consolidated and standalone financial statements contained no qualifications or adverse remarks.
Voting was conducted electronically via the National Securities Depository Limited (NSDL) platform. Remote e-voting was open from September 18, 2026, to September 22, 2026. Nidhi Shree J, Partner at M/s. V Sreedharan & Associates, served as the scrutinizer. Results were declared within two working days, with the scrutinizer report dated September 24, 2026.
Attendance and participation
A total of 81 shareholders holding 34,604,605 shares attended the meeting physically or via proxy, while 81 shareholders attended through video conferencing (16 promoters and 65 public). The quorum was confirmed by NSDL prior to proceedings. Key management personnel, including Chief Financial Officer Anurag Bhagania, participated from the corporate office in Bengaluru. Several independent directors joined via video conference, including Debarati Sen, Dr. Claudio Albrecht, Colin Bond, Dr. Rashmi Barbhaiya, Vijay Karwal, and Bharat D Shah.
Representatives from the outgoing auditors, Deloitte Haskins & Sells, and proposed auditors, B S R & Co LLP, were present.
What the Numbers Show
The voting data reveals a divergence in shareholder sentiment across different agenda items. While routine matters like financial statement adoption garnered near-unanimous support (99.75% in favour), the special resolution for additional remuneration to Managing Director Neeraj Sharma faced higher opposition, with 5.54% of votes cast against it. This contrasts sharply with the material related party transactions with Strides Pharma entities, which saw only 0.01% opposition among eligible voters, indicating strong institutional confidence in these operational linkages despite promoter interest.
Historical Stock Returns for Onesource Specialty Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.93% | -6.48% | -14.41% | -9.27% | -25.99% | -20.08% |
How might the transition from Deloitte to B S R & Co LLP influence OneSource Specialty Pharma's audit findings or compliance posture over the next five years?
What specific operational synergies are expected from the material related party transactions with Strides Pharma Science Ltd and Strides Pharma Inc, USA?
Will the 5.54% shareholder opposition to the Managing Director's additional remuneration impact future executive compensation negotiations or corporate governance reforms?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
